Stock 4162 PHARMAENGINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company PharmaEngine, Inc.

Equities

4162

TW0004162003

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
91.5 TWD +0.99% Intraday chart for PharmaEngine, Inc. +2.81% -13.27%
Apr. 24 PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors CI
Mar. 18 PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC CI

Business Summary

PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,

Sales per Business

TWD in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
654 100.0 % 768 100.0 % +17.31%

Sales per region

TWD in Million2022Weight2023Weight Delta
Taiwan
100.0 %
654 100.0 % 768 100.0 % +17.31%

Managers

Managers TitleAgeSince
Hong Ren Wang CEO
 Chief Executive Officer - -
Yu Syuan Tsao DFI
 Director of Finance/CFO - 21-05-16
Po Nien Shen CTO
 Chief Tech/Sci/R&D Officer - 12-12-31
Chi Hsing Chang IRC
 Investor Relations Contact - 03-01-31
Peter Wu IRO
 Public Communications Contact - 04-06-30
Hui Ying Kuo PRN
 Corporate Officer/Principal - 12-12-31

Members of the board

Members of the board TitleAgeSince
Jui Wen Wu BRD
 Director/Board Member - 18-01-18
Zhi Li Wang BRD
 Director/Board Member - 19-06-12
Yi Hui Lin BRD
 Director/Board Member - 18-05-14
Jan Yau Hsu CHM
 Chairman - -
Ming Shiang Wu BRD
 Director/Board Member - -
Wen Hong Hsu BRD
 Director/Board Member - -
Ming Feng Hou BRD
 Director/Board Member - -
Chien Huang Lin BRD
 Director/Board Member - 21-08-25
Ming Daw Chang BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 145,678,240 91,695,240 ( 62.94 %) 2,000,000 ( 1.373 %) 62.94 %

Shareholders

NameEquities%Valuation
First Securities Investment Trust Co. Ltd.
0.3689 %
537,335 0.3689 % 2 M NT$
Hua Nan Securities Investment Trust Co. Ltd.
0.0338 %
49,198 0.0338 % 152 497 NT$
OP Investment Management Ltd.
0.0216 %
31,435 0.0216 % 97 438 NT$
HSBC Global Asset Management (Taiwan) Ltd.
0.0178 %
26,000 0.0178 % 80 591 NT$
Daiwa Asset Management (H.K.) Ltd.
0.0125 %
18,274 0.0125 % 56 643 NT$

Company contact information

PharmaEngine, Inc.

10, Section 3, Minsheng East Road 11th Floor

104 80, Taipei

+

http://www.pharmaengine.com
address PharmaEngine, Inc.(4162)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
91.5
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PHARMAENGINE, INC. Stock PharmaEngine, Inc.
-13.27% 403M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4162 Stock
  4. Company PharmaEngine, Inc.